Our results demonstrated that synergism blockade CD47 and CD274 antibody in cancer can also inhibit tumor growth and CTCs metastasis in vivo (Fig. 3), which may block CD47 binding to SIPR-α and PD-L1 binding to PD-1. Here, CD47 is linked to neoplasm.